Corbus Pharmaceuticals
CRBP
81 hedge funds and large institutions have $114M invested in Corbus Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 29 increasing their positions, 18 reducing their positions, and 17 closing their positions.
61% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 18
0.05% more ownership
Funds ownership: 1.37% → 1.42% (+0.05%)
0% more funds holding
Funds holding: 81 → 81 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 17
21% less capital invested
Capital invested by funds: $144M → $114M (-$30.1M)
38% less call options, than puts
Call options by funds: $510K | Put options by funds: $825K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IA
IFP Advisors
Tampa,
Florida
|
+$3.03M |
| 2 |
BlackRock
New York
|
+$1.91M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.31M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.09M |
| 5 |
Renaissance Technologies
New York
|
+$1.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$3.79M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$2.5M |
| 3 |
Jennison Associates
New York
|
-$1.26M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$612K |
| 5 |
QIM
Quantitative Investment Management
Charlottesville,
Virginia
|
-$220K |
CRBP Hedge Fund Activity: Q2 2018 in Review
81 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q2 2018, worth a combined $114M — down 21% from $144M a quarter earlier.
Fund positioning in CRBP was balanced in Q2 2018: 17 funds opened new positions, 17 closed out, 29 added to existing stakes and 18 trimmed.
The largest buyer was IFP Advisors, adding an estimated $3.03M. The largest seller was ETF Managers Group, cutting an estimated $3.79M.
- 81 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $114M of Corbus Pharmaceuticals stock for Q2 2018, down 21% quarter-over-quarter.
- 17 funds opened new Corbus Pharmaceuticals positions in Q2 2018 and 17 closed out, a net change of 0 holders.
- The largest Corbus Pharmaceuticals buyer in Q2 2018 was IFP Advisors, an estimated $3.03M added.
- The largest Corbus Pharmaceuticals seller in Q2 2018 was ETF Managers Group, an estimated $3.79M sold.
Based on aggregated 13F filings for Q2 2018.